Tefferi, A., Barosi, G., Mesa, R.A., Cervantes, F., Deeg, H.J., Reilly, J.T., ...
Myelofibrosis with myeloid metaplasia (MMM) is a clinicopathologic entity characterized by stem cell-derived clonal myeloproliferation, ineffective erythropoiesis, extramedullary hematopoiesis, and...
Dingli, D. F. H., Mahaffey, V., Spurbeck, J., Ross, F. M., Watmore, A. E., Reilly, J. T., ...
Chromosome anomalies are detected in approximately half of patients with myelofibrosis with myeloid metaplasia (MMM) although none of the most prevalent lesions are specific to the disease. In a...
Imatinib for systemic mast-cell disease (2003)
Pardanani, A., Elliott, M., Reeder, T., Li, C.Y., Baxter, E.J., Cross, N.C., ...
Imatinib has shown to be effective against malignant disease driven by ckit. We prospectively treated 12 adults with symptomatic systemic mast-cell disease at a dose of either 100 mg or 400 mg per...
Imatinib for systemic mast-cell disease (2003)
Pardanani, A., Elliott, M., Reeder, T., Li, C.Y., Baxter, E.J., Cross, N.C.P., ...
Imatinib has shown to be effective against malignant disease driven by ckit. We prospectively treated 12 adults with symptomatic systemic mast-cell disease at a dose of either 100 mg or 400 mg per...
Pardanani, A., Ketterling, R.P., Brockman, S.R., Flynn, H.C., Paternoster, S.F., Shearer, B.M., ...
Imatinib mesylate is effective in the treatment of hematologic malignancies that are characterized by either abl- or PDGFR beta- activating mutations. The drug is also active in a subset of patients...
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders (2003)
Pardanani, A., Reeder, T., Porrata, L.F., Li, C.Y., Tazelaar, H.D., Baxter, E.J., ...
Imatinib mesylate (Gleevec), a small molecule inhibitor of abl, kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases, has been reported to be effective in the treatment of...
Environmental chemical exposures and disturbances of heme synthesis.
Daniell, W E, Stockbridge, H L, Labbe, R F, Woods, J S, Anderson, K E, Bissell, D M, ...
Porphyrias are relatively uncommon inherited or acquired disorders in which clinical manifestations are attributable to a disturbance of heme synthesis (porphyrin metabolism), usually in association...
Environmental chemical exposures and disturbances of heme synthesis.
Daniell, W E, Stockbridge, H L, Labbe, R F, Woods, J S, Anderson, K E, Bissell, D M, ...
Porphyrias are relatively uncommon inherited or acquired disorders in which clinical manifestations are attributable to a disturbance of heme synthesis (porphyrin metabolism), usually in association...
Kipps, T. J., Robbins, B. A., Tefferi, A., Meisenholder, G., Banks, P. M., Carson, D. A.
Using monoclonal antibodies (MAb) specific for cross-reactive idiotypes (CRIs) associated with human monoclonal IgM autoantibodies, we examined 57 biopsy specimens that previously had been noted to...